whose neuroimaging appearance was consistent with cranial or spinal meningioma, ependymoma, or non-VS. These patients were brought to our attention by members of the Department of Neurosurgery, Massachusetts General Hospital; through referral to the Neurofibromatosis Clinics, Massachusetts General Hospital and University Hospital Eppendorf, by outside physicians; or through enrollment in our other research studies. Comprehensive review of patient records was conducted, with particular attention paid to clinical course, surgeries, pathology reports, and family history. To exclude the presence of a contralateral small VS on presentation, at least one skull base MR image (axial minimal postcontrast slice thickness of 3 mm) negative for contralateral tumor was reviewed by a study team member. Given that children may harbor very small tumors, we also excluded any patient who had not undergone such an imaging study after the age of 18 years.
Genomic DNA was extracted from peripheral blood leukocytes or from Epstein-Barr virus-transformed lymphoblastoid cell lines. Tumor tissue was collected at the time of clinically indicated surgical procedures after the treating pathologist had retained all materials needed for diagnosis. When prospectively acquired tumor tissue was unavailable, paraffin blocks were retrieved from the pathology depart- M  back pain  0  0  2  0  0  0  none  19  23, M  calf mass  0  0  NE  NE  0  1  amblyopia  20  38, M  diplopia  0  1  NE  NE  0  0  none  21  21, M  hearing loss  0  1  9  0  0  0  N E  22  54, F  motion sickness  1  0  NE  NE  0  0  NE  23  59, F  hearing loss  2  0  0  0  0  0  NE  24  41, M  tinnitus  3  0  4  0  0  0  none  25  30, F  tinnitus  3  0  4  1  0  0  none  26  34, F  hearing loss  1  0  2  0  0  0  NE  27  39, M  tinnitus  0  0  1  0  0  0  NE  28  48, M  incidental finding  0  1  0  0  0  0  NE  29  24, F  tinnitus, loss of  1  0  1  0  0  0  NE  balance, hearing loss  30  25, F  hearing loss  3  1  0  0  0  0  none  31  24, F  hearing loss  1  0  0  0  0  0  none  32  19, F  dizziness  1  2  1  0  0  0  amblyopia  33  49, F  decreased coordination  2  2  1  0  2  0  NE  34  34, M  tinnitus  0  0  1  0  2  0  none  35  26, F  foot pain  5  0  3  0  2  1  none  36  21, F  tinnitus  1  1  6  0  0  0  none  37  63, F  paraparesis  0  0  2  0  2  0  none  38  31, M  hearing loss, tinnitus  4  0  1  0  0  0  none  39  42, F  hearing loss  4  0  0  1  0  0  none  40  34, F  incidental finding  7  0  0  0  0  0  2 cataracts  41  41, F  skin lesions  1  0  1  0  2  2  none  42  33, M  dysphagia  1  3  4  0  1  0  none  43  24, M  calf mass  2  0  8  0  3  0  none  44 26, F hyperacusis 0 1 4 0 0 0 2 cataracts * EM = extramedullary; IM = intramedullary; MG = meningioma; NE = not evaluated. ment archives of treating institutions. Pathological reports were reviewed to identify tumor blocks containing predominantly a single tumor when more than one tumor had been removed at surgery. Genomic DNA extraction from frozen tumors, paraffin-embedded tumors, and blood samples was performed as previously described. 8 The present study was approved by the institutional review boards of participating centers, and informed consent was obtained from all persons donating tissue.
Mutational analysis of the NF2 gene was performed as previously described. 8 Briefly, the 15 exons of the NF2 gene reported to harbor pathogenic alterations were amplified from genomic tumor DNA and scanned using single-strand conformational polymorphism or temperature-gradient gel electrophoresis. Samples from the SSCP were either labeled with alpha-33 P deoxyadenosine 5Ј-triphosphate and separated on polyacrylamide gels or separated on GenePhor premade gels using the Gene Gel Excel system (Pharmacia Biotech, Piscataway, NJ) with subsequent silver staining. When aberrations were detected with these methods, sequencing was performed bidirectionally using a Big Dye sequencing kit (Applied Biosystems, Foster City, CA) or through manual sequencing with a radiolabeled terminator cycle sequencing kit (USB, Cleveland, OH).
When alterations were found in a tumor DNA sample, the matched blood specimen and, when available, a second anatomically distinct tumor were amplified and sequenced side by side with the tumor specimen. When alterations were predicted to create or destroy a restriction enzyme site, restriction enzyme digestion was performed with the exon in question and the products were subsequently separated on agarose or acrylamide gels.
Loss of the NF2 region on chromosome 22 was determined using a panel of flanking and intragenic microsatellite markers. Note that CRYB2 D22S275 and D22S193 are centromeric to the NF2 gene, D22S929 and NF2tet are intragenic, and D22S268 and D22S430 are telomeric. The total distance from the most centromeric marker (CRYB2) to the most telomeric (D22S430) is 5 megabases. The LOH analysis was performed as previously described. 8 
Results
We identified 44 individuals who met the aforementioned study entry criteria; 28 were female and 16 were male (female/male ratio 1.8:1; Table 1 ). In five of these 44 patients, intracranial tumors were incidental findings on imaging studies obtained to evaluate nonspecific symptoms such as headache. These five patients were a mean age of 35 years at the time of the initial cranial imaging study positive for a lesion, whereas the other 39 patients first exhibited symptoms attributable to an NF2-related lesion at ages ranging from 11 to 63 years, with a mean age of 32 years. The age at symptom onset or at the time of diagnostic imaging positive for the presence of unilateral VSs (whichever came first) in the entire study population ranged from 19 to 71 years, with a mean age of 37 years. Twenty-two (50%) of 44 patients presented with symptoms of eighth cranial nerve dysfunction. The 16 patients who had presented with tumors other than unilateral VSs experienced VS-related symptoms a mean of 10 years (range 1-35 years) after having presented with symptoms attributable to the first tumor. Twenty-eight of the VSs were right sided, and 16 were left sided (right/left ratio 1.8:1).
The time from symptom onset to diagnosis of the first lesion ranged from 0 to 36 years (mean 4.3 years). Twentysix patients (59%) were found to have more than one tumor at the time of diagnosis; in the remaining 18 patients, there was a lag of 1 to 26 years (mean 10 years) before recognition of a second tumor.
The tumor burden in this group varied widely. Thirtynine of 44 patients had intracranial tumors other than unilateral VSs, including 33 with meningiomas and 17 with skull base non-VS lesions. Of the 143 nonunilateral VSs that were nonmidline, 93 (65%) were ipsilateral to the unilateral VS (Fig. 1) . Furthermore, in 16 (36%) of 44 patients, all nonunilateral VSs were ipsilateral to the unilateral VS; in only four patients were such lesions limited to the contralateral side of the head (p = 0.01, McNemar test). Thirty-seven of 44 patients had undergone cervical spine MR imaging studies, which revealed tumors in 12 (32%; 14 extramedullary tumors consistent with schwannoma or meningioma and two intramedullary tumors consistent with ependymoma). Thirty patients underwent thoracic spine MR imaging, and 16 had spinal tumors (53%; 32 extramedullary and one intramedullary tumor). Thirty-one patients underwent lumbar spine MR imaging, with 20 having tumors (65%; 32 involving the conus and cauda equina and one intramedullary lesion). The mean tumor burden per patient in the entire cohort was 2.9 intracranial nonunilateral VSs (range zero-10 lesions, median two) and 2.3 spinal tumors (range zero-nine lesions, median one lesion) per patient among the 37 who had undergone spinal imaging.
Thirty-one patients had undergone ophthalmological evaluation with specific attention to NF2 manifestations; findings included childhood amblyopia and strabismus in two (6%) and six cataracts in four patients (13%). No pa- tient was found to have retinal hamartoma or epiretinal membrane.
No patient reported a parent or sibling with a schwannoma, a meningioma, or unexplained hearing loss at a young age. Sixteen of the 44 patients had no children; the remaining 28 patients had 63 children. The ages of 62 of these 63 children were known and ranged from 6 months to 54 years at the time of the patient's last visit. Ten of the 62 were older than the parent had been at the time of the first symptom; 33 of 62 were older than the 20.3-year mean of symptom onset for NF2 reported by Parry, et al. 13 Sixty-one of 63 children had no NF2-related findings according to the patient's report; two children of two different patients had isolated NF2-related findings. One child had unilateral VS at the age of 21 years, without other NF2 manifestations at the age of 24 years, and was born to a parent (Case 15) who first had symptoms (attributable to unilateral VS) at the age of 46 years. The other child had bilateral cataracts at the age of 32 years, no abnormalities on cranial MR imaging and no other NF2 manifestations as of the age of 35 years, and had been born to a parent (Case 39) who first experienced symptoms at the age of 42 years and did not herself have cataracts.
The mean follow up in these patients was 14 years (range A contralateral VS subsequently developed in four patients 3, 17, 24, and 46 years after the onset of unilateral symptoms (Cases 12, 7, 6, and 32, respectively; Fig. 2) ; two (Cases 6 and 7) suffered hearing loss rapidly progressing to total deafness. The number of years from VS symptom onset until the most recent MR image showing no contralateral VS ranged from 1 to 40 years (mean 10 years). A Kaplan-Meier analysis of the number of years without contralateral VS in 40 patients and the number of years until the development of contralateral VS in the other four patients yielded actuarial chances of contralateral VS development to be 2.9% at 3 to 17 years (95% CI 0-8.4%), 11% at 18 to 24 years (95% CI 0-27%), and 28.8% at 25 to 40 years (95% CI 0-62.6%) after VS symptom onset (Fig. 3) .
Adequate quality tumor DNA was available in 26 of these patients for complete screening of the NF2 locus (Fig.  4) . Two other tumors could be partially screened from paraffin-blocked DNA. Twenty mutations were detected in 17 tumors including 13 nonsense mutations, four frameshift mutations, and three splice site alterations (Table 2 ). In two tumors, mutations were detected at a very low level, suggesting contamination by normal tissue or somatic mutations obscured by the presence of a second tumor. Loss of heterozygosity of the NF2 region markers was present in 14 (50%) of 28 tumors. Of these 20 mutations, four were detectable at a low level in blood samples, confirming the presence of somatic mutation. Second pathologically or anatomically distinct tumors were available in nine cases. Seven exhibited the same mutation demonstrated in the first tumor, and one (Case 10) shared the LOH but not the mutation, suggesting mosaicism for deletion of the NF2 locus.
Discussion
In this report, we describe the presentation and clinical course of 44 patients with a previously undescribed syndrome of unilateral VS and other NF2-related tumors. Our patients differed significantly from both patients with classic NF2 and those with isolated unilateral VS. For example, the mean age (37 years) at onset of eighth nerve dysfunction in these patients was between the mean age (17-22 years) 5, 11, 13 at onset of NF2 and that (55 years) of unilateral sporadic VS.
14 The low incidence of ocular findings was especially surprising, with only four of 31 patients having cataracts and none having retinal pathological features compared with a 73 to 81% incidence of cataracts 12, 13 and an 80% incidence of retinal pathologies 12 reported in studies of patients with classic NF2. Conversely, patients in our study shared many features with patients with classic NF2. Unilateral hearing loss is the most common initial symptom of NF2, 5 and half of the patients in the current series presented with symptoms of eighth nerve dysfunction. In addition, the large proportion of patients with cranial meningiomas and spinal cord tumors among those with this phenotype-72 and 75%, respectively, of those who had undergone imaging studies-was similar to that reported in large series of patients with NF2 in whom meningiomas and spinal cord tumors were found in 58 and 90%, respectively. 11 Most of the spinal tumors in these patients were asymptomatic, a finding comparable to that in one study in which two thirds of the patients with NF2 harbored asymptomatic spinal tumors. Perhaps most frustrating was the prolonged time This alteration is present at a less than heterozygous level in the blood, in a fully heterozygous level in tumor 1, and at a hemizygous level in tumor 2. C: Results of microsatellite analysis revealing LOH in tumor 2 (asterisks) compared with a blood sample in both the centromeric marker D22S275 and the telomeric marker D22S268. Tumor 1 retains both alleles in these markers and carries an unrelated mutation in exon 3 not seen in tumor 2.
between symptom onset and correct diagnosis, which was similar to the time documented in studies of NF2. 13 We hypothesized that this phenotype might be explained by somatic mosaicism at the NF2 locus, which was confirmed in eight patients. Molecular definition was facilitated by access to tumor tissues in all cases. Mosaicism may account for some of the phenotypic observations we described, for example, the preponderance of ipsilateral tumors. In addition, the reduced incidence of ocular findings in these patients may be due to cells contributing to the eye layers diverging earlier from a cell of origin than Schwann cells or arachnoid cap cells. It is not clear to what extent postzygotic mutations leading to somatic mosaicism will also affect the germline causing germline mosaicism, although we observed a markedly reduced risk of genetic transmission. Conversely, we predicted that any affected offspring would display the full NF2 phenotype rather than a mosaic one and that such patients deserve careful genetic counseling. Finally, although NF2 affects males and females equally, 4 there was a female preponderance in the patients described in the present report. It has been shown that meningiomas are more common in female patients with NF2 than in males. 3 Indeed, there were 10 patients in this report whose tumor other than the unilateral VS was a meningioma, and nine of these patients were female, accounting for a significant portion of the sex imbalance in the cohort of patients with this phenotype. Thus, the slight female preponderance of patients in this series could reflect a tendency for the mosaic inactivation to occur more frequently in meningioma precursor cells combined with the demonstrated tendency for meningiomas whose formation is driven by an NF2 mutation more commonly to grow to the point of radiographic detectability in females. 3 Mosaicism is an increasingly recognized factor in human genetic disease. Tumor suppressor gene syndromes are especially powerful models for study of mosaicism because tumor development provides ready phenotypic identification of affected tissue. As a result, mosaicism has already been described for tuberous sclerosis 1 and NF Type 1. 15 Authors of a recent study of patients with bilateral VSs estimated that 25% of patients with NF2 and new mutations are mosaic 8 and a small number of patients with schwannomatosis have been shown to be mosaic for the NF2 mutation. 6 The patients in this report represent a third phenotypic pool of NF2 mosaics. This phenotype is particularly important for the neurosurgeon to recognize; although the finding of bilateral VS almost always leads appropriately to referral to a specialist, unilateral VS combined with another NF2-related feature might be attributed to coincidence while overlooking the need for patients with these pathological entities to undergo specialist evaluation including full cranial and spinal imaging and ophthalmological studies. In addition, the definitive diagnosis of NF2 mosaicism requires tumor tissue, underscoring the need to bank tumors for patients who might desire genetic diagnosis in the future.
The present study is especially important when considering the surgical management of unilateral VSs in this population. In treating a patient with this phenotype, the neurosurgeon must consider the risk of the contralateral VS development, which reached almost 29% in the present study 25 years after patients first experienced symptoms from the unilateral VS. Our results support aggressive man- C1084T (NS) yes yes § NA mosaic * FS = frameshift; NA = not available; NS = nonsense; SP = splice site alteration. † Nucleotide positions are numbered according to the complementary DNA sequence, with the first nucleotide of the ATG initiation codon numbered as 1. Positions for introns are based on the genomic sequence numbered from the closest exonic position.
‡ Tumor also carried a second mutation: 323 del 1 bp (FS). § Mutations were seen at a less than heterozygous level. || Previously reported by Jacoby, et al., 1997. ** Tumor DNA was of insufficient quality for a complete screening. † † Previously reported by Kluwe and Mautner, 1998. agement of small tumors to preserve hearing in patients with this phenotype, which is similar to the strategy currently recommended for patients with NF2. 2 Patients who present with large unilateral VS and nonsalvageable hearing should undergo decompression or, when possible, complete lesion removal tempered by concern for facial nerve function. The unique challenge in patients with this phenotype is the presence of intermediate unilateral VS size when the potential benefit of hearing preservation must be weighed against the risk of hearing loss combined with the unique risk of contralateral VS development.
Conclusions
In summary, neurosurgeons who encounter patients with unilateral VS and one or more NF2-related tumors should consider referral to a NF specialist for full craniospinal imaging, ophthalmological examination, and genetic testing. The two important features of this phenotype are a tangible long-term risk for developing contralateral VS and minimal genetic risk. Neurosurgeons resecting tumors in patients with this phenotype should consider tumor banking to facilitate molecular diagnostics.
